Related Experiment Video
Updated: Aug 29, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Influence of the hepatitis B e antigen/anti-HBe status on the response to lamivudine
1Department of Gastroenterology, Toranomon Hospital, 2-2-2, Minato-ku, Tokyo 105-8470, Japan. fumitakas@toranomon.gr.jp
Objective:
The optimal therapeutic regimen of lamivudine for chronic hepatitis B is not agreed upon, especially with reference to hepatitis B e antigen (HBeAg) or the corresponding antibody (anti-HBe) in sera of patients.
Methods:
We analyzed 249 Japanese patients with chronic HBV infection who were treated with lamivudine for more than 12 months. HBeAg was detected in sera from 117 of them (47%). HBV DNA sequences in serum samples from the pretreatment period and during therapy were amplified by polymerase chain reaction, and analyzed for mutations.
Results:
Lamivudine normalized serum levels of alanine aminotransferase at 6 and 12 months, and suppressed serum HBV DNA to levels undetectable by the bDNA method in most patients. Lamivudine suppressed HBV DNA levels to a greater extent in patients with anti-HBe than HBeAg. In patients treated with lamivudine for 5 years, HBV mutants with mutations in the precore region and core promoter reverted to the wild-type in some of them within 1 year.
Conclusion:
Lamivudine induces a better response in patients without than in those with HBeAg. It initially selects the wild-type HBV from among precore or core promoter mutants.
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Retrovirus Life Cycles
Hepatic Drug Excretion: Influencing Factors
